Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities

PIC 024-4 and PRO 2000 are naphthalene sulfonate polymers that bind to CD4 with nanomolar affinity and block binding of gp120. Both have activity against human immunodeficiency virus type 1 in H9 cells, peripheral blood mononuclear cells, and primary monocyte/macrophages, are synergistic with zidovudine, and do not inhibit tetanus toxoid-stimulated T-cell proliferation at anti-human immunodeficiency virus type 1 concentrations.

[1]  D. Markovitz,et al.  The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.

[2]  D. Richman,et al.  Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds , 1994, Antimicrobial Agents and Chemotherapy.

[3]  T. Chou,et al.  Synergism and antagonism in chemotherapy , 1991 .

[4]  M. Hirsch,et al.  Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, The Journal of infectious diseases.

[5]  R. Chaisson,et al.  Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection , 1991, Antimicrobial Agents and Chemotherapy.

[6]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[7]  M. Baba,et al.  Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2. , 1991, Journal of medicinal chemistry.

[8]  E. De Clercq,et al.  Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. , 1992, Antiviral research.

[9]  Roy E. Byington,et al.  Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.

[10]  D. Ho,et al.  Biological cloning of functionally diverse quasispecies of HIV-1. , 1993, AIDS research and human retroviruses.

[11]  L. Callahan,et al.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions , 1991, Journal of virology.

[12]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[13]  E. De Clercq,et al.  Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. , 1991, Journal of medicinal chemistry.

[14]  L. D. Ward,et al.  Measurement of ligand binding to proteins by fluorescence spectroscopy. , 1985, Methods in enzymology.

[15]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[16]  E. De Clercq,et al.  Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. , 1991, Journal of medicinal chemistry.

[17]  S. Lederman,et al.  Sulfated polyester interactions with the CD4 molecule and with the third variable loop domain (v3) of gp120 are chemically distinct. , 1992, AIDS research and human retroviruses.

[18]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[19]  E. Reinherz,et al.  A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice , 1993, The Journal of experimental medicine.

[20]  T. A. Hagan,et al.  Detection , Isolation , and Continuous Production of Cytopathic Retroviruses ( HTLV-III ) from Patients with AIDS and Pre-AIDS , 2022 .